- Chemgenex Pharmaceuticals, Inc. (NASDAQ:CXSP)
- Carmel Biosensors
- CPG, Inc.
- Inovio Biomedical Corporation (AMEX:INO)
- Nventa Biopharmaceuticals Corporation (TSX:NVN)
- Response Biomedical Corporation (TSX-V:RBM)
- XL TechGroup, Inc. (AIM:XLT)
- State Government of Victoria, Australia, Department of Innovation, Industry and Regional Development
 |
Chemgenex Pharmaceuticals, Inc. (NASDAQ:CXSP)ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes, obesity, and depression. ChemGenex harnesses the power of genomics for target discovery and validation, and in clinical trials to develop more individualized therapeutic outcomes. ChemGenex's lead compound, Ceflatonin®, is currently in phase 2 clinical trials for leukemia and Quinamed® is in phase 2 clinical trials for prostate, breast and ovarian cancers. The company has a significant portfolio of anti-cancer, diabetes, obesity and depression programs, several of which have been partnered with international pharmaceutical companies. Katan assisted Chemgenex in the early implementation of its strategic development. |
Carmel BiosensorsCarmel Biosensors developed hypersensitive biological sensors to measure physiological parameters specifically, the level of various substances in the body, such as hormones, drugs, and glucose. Katan advised Carmel on its overall capitalization strategy and business plan and assisted in the identification of a top tier investment banker in the United States. In October 1999, Katan assisted in the facilitation of a research and development collaboration with Medtronic, Inc., (NYSE:MDT) for advanced biosensors for various medical applications. |
 |
CPG, Inc.CPG, Inc. was a leading suppler of DNA synthesis and purification materials providing the base material for its industry-leading Prosep®-A High Capacity Chromatographic Media. In 2002, Katan advised CPG, Inc., on its acquisition by Millipore, Inc. (NYSE:MIL). |
 |
Inovio Biomedical Corporation (AMEX:INO)Inovio Biomedical Corporation is a late stage biomedical company focused on commercializing its proprietary Selective Electrochemical Tumor Ablation (SECTA) therapy and development of multiple DNA vaccines using its delivery platform for gene-based treatments. Katan assisted in the formation of Inovio's predecessor company, Genetronics, Inc., created its overall business strategy, developed its strategic capitalization strategy and Stan was a member of the Board of Directors for over 10 years. In 2003, Katan facilitated the sale of Inovio's BTX Division to Harvard Bioscience, Inc. (NASDAQ: HBIO). |
 |
Nventa Biopharmaceuticals Corporation (TSX:NVN)Nventa Biopharmaceuticals Corporation is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). Katan is an active advisor to Nventa on its overall corporate strategy. |
 |
Response Biomedical Corporation (TSX-V:RBM)Response Biomedical develops, manufactures, and markets rapid on-site diagnostic tests for use with its portable RAMP Platform for clinical and environmental applications. RAMP represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. Katan has assisted in shaping Response's overall strategy. Stan is a former member of the Company's Board of Directors. |
 |
XL TechGroup, Inc. (AIM:XLT)XL TechGroup identifies unmet market needs in the biotech, ecotech, and medtech sectors and then systematically creates and develops successful disruptive technology businesses to exploit these needs. The Company has developed a unique proven method to rapidly bring companies from inception to liquidity, matching unexploited IP from a group of corporate and technology partners to the identified unmet market need. Katan has assisted in shaping the Company's overall strategy and currently maintains a strong relationship with this innovative group. |
 |
State Government of Victoria, Australia, DIIRDThe Department of Innovation, Industry and Regional Development (DIIRD) is the Victorian Government's lead agency for economic and regional development. Government's goals for more quality jobs and thriving, innovative industries across Victoria will be fostered through DIIRD's five priority objectives: Investment Attraction, Trade Development, Developing Innovative Industries, Regional Development and Marketing Victoria. Since 2001, Katan has acted as advisors to the State Government on the commercialization of biotechnology within Victoria. |
